MedTrace Logo

Prognostic Accuracy of ST2 Dynamics in Ischemic Stroke Outcome

NCT04607031 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-07-28

No results posted yet for this study

Summary

Early outcome prediction after ischemic stroke (IS) is of great importance. Prognosis is usually based on clinical variables and neuroradiological findings while serum biomarkers may contribute to prognostic accuracy. Inflammatory biomarker Suppression of Tumorigenicity 2 (ST2) has been shown as promising in IMU outcome predicting. The relationship between ST2 serum values and IS severity is not fully clarified. The proposed hypothesis is that earlier releasing and higher ST2 serum concentrations will be associated with a worse IS outcome. In this prospective and observational study 20 patients with IS will be included and followed. The primary outcome is functional outcome according to the modified Ranking scale at 90 days. In case of hypothesis confirmation, theoretical contribution will be in a better understanding of pathophysiological changes in acute phase of IS, while the clinical purpose is to improve the prognostic procedure.

Conditions

Interventions

DIAGNOSTIC_TEST

measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke

7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications

Sponsors & Collaborators

  • General Hospital Sveti Duh

    lead OTHER

Principal Investigators

  • Ana Sruk, MD · GH Sveti Duh, Zagreb, Croatia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2020-03-31
Completion
2021-03-31

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04607031 on ClinicalTrials.gov